Abstract
No one has yet found an AIDS vaccine that can trigger effective antibodies against HIV's surface protein. So Merck has constructed a vaccine that abandons antibodies altogether, and the company is testing it in a fast-tracked study to determine whether it's worth pursuing the approach.

This publication has 0 references indexed in Scilit: